Deepak Cyril Dsouza, MBBS, MD

• Aarti Gupta
• Alan Anticevic
• Amir Garakani
• Ashley Schnakenberg Martin
• Brian Pittman
• Cenk Tek
• Christopher Van Dyck
• David Labaree
• David Matuskey
• David Tolin
• Edward Perry
• Elizabeth Ralevski
• Emmanuelle Schindler
• Evan Morris
• Gerard Sanacora
• Gihyun Yoon
• Godfrey Pearlson
• Graeme Mason
• Graham Williams
• Handan Gunduz-Bruce
• Irina Esterlis
• Ismene Petrakis
• Jason Gerrard
• Jason Johannesen
• Jean-Dominique Gallezot
• Jim Ropchan
• Joao P. De Aquino
• John Cahill
• John Krystal
• Jordan Sloshower
• Jose Cortes-Briones
• Joseph Erdos
• Joseph Lucien Goulet
• Keith Hawkins
• Kelly Cosgrove
• Kyung-Heup Ahn
• Larry Davidson
• Louis Trevisan
• Marina Picciotto
• Michael Bloch
• Michael Campbell
• Mihaly Hajos
• Mohamed Sherif
• Mohini Ranganathan
• Morris Bell
• Nabeel Nabulsi
• Naomi Driesen
• Patrick Skosnik
• Peter Morgan
• Philip Corlett
• Rajiv Radhakrishnan
• Ralitza Gueorguieva
• Richard Carson
• Robert Rohrbaugh
• Samuel Ball
• Samuel Wilkinson
• Scott Woods
• Sherry McKee
• Somaia Mohamed
• Stacy Castner
• Stephanie O'Malley
• Stephanie Yarnell-Mac Grory
• Suhas Ganesh
• Susan Nappi
• Thomas McGlashan
• Toral Surti
• Vince Calhoun
• Vinod Srihari
• Yiyun Huang
• Zoran Zimolo
• Zubin Bhagwagar

Behavior and Behavior Mechanisms; Mental Disorders; Behavioral Disciplines and Activities; Psychological Phenomena; Psychiatry and Psychology

• The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2004, 29:1558-72.
• Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57:594-608.
• Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.Krystal JH, Perry EB, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D'Souza DC. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Archives Of General Psychiatry 2005, 62:985-94.
• Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia.D'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH. Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2006, 31:2767-75.
• gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation.D'Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, Boutros NN, Cooper T, Seibyl J, Krystal JH. gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biological Psychiatry 2006, 59:128-37.
• The acute effects of cannabinoids on memory in humans: a review.Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006, 188:425-44.
• Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans.D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2008, 198:587-603.
• IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans.D'Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry 2000, 47:450-62.
• The effects of cannabinoids on serum cortisol and prolactin in humans.Ranganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, D'Souza DC. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology 2009, 203:737-44.
• Cannabis and psychosis/schizophrenia: human studies.D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives Of Psychiatry And Clinical Neuroscience 2009, 259:413-31.
• Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.D'Souza DC, Bennett A, Abi-Dargham A, Krystal JH. Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient. Journal Of Clinical Psychopharmacology 1994, 14:361-3.
• Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB, Suckow RF, Stetson P, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 1998, 135:213-29.
• The NMDA antagonist model for schizophrenia: promise and pitfalls.Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998, 31 Suppl 2:104-9.
• D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia.Krystal JH, D'Souza DC. D-serine and the therapeutic challenge posed by the N-methyl-D-aspartate antagonist model of schizophrenia. Biological Psychiatry 1998, 44:1075-6.
• Interactive effects of subanesthetic ketamine and haloperidol in healthy humans.Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB, Vegso S, Heninger GR, Charney DS. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 1999, 145:193-204.
• Symptom provocation studies in psychiatric disorders: scientific value, risks, and future.D'Souza DC, Berman RM, Krystal JH, Charney DS. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry 1999, 46:1060-80.
• Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients.Krystal JH, D'Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35 Suppl:S35-49.
• NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Review Of Psychiatry 1999, 7:125-43.
• Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions.Krystal JH, Bennett A, Abi-Saab D, Belger A, Karper LP, D'Souza DC, Lipschitz D, Abi-Dargham A, Charney DS. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biological Psychiatry 2000, 47:137-43.
• Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biological Psychiatry 2000, 47:371-9.
• Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders.Krystal JH, D'Souza DC, Sanacora G, Goddard AW, Charney DS. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders. The Medical Clinics Of North America 2001, 85:559-77.
• Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D(2) receptor".Krystal JH, D'Souza DC. Comment on "Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D(2) receptor". Biological Psychiatry 2001, 50:555-6.
• Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162:55-62.
• NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D'Souza DC. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy. Annals Of The New York Academy Of Sciences 2003, 1003:176-84.
• N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability.Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99:79-94.
• Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients.Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2003, 28:2020-8.
• NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169:215-33.
• Nicotine effects on brain function and functional connectivity in schizophrenia.Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biological Psychiatry 2004, 55:850-8.
• Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005, 179:303-9.
• Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine.Cho HS, D'Souza DC, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology 2005, 179:136-43.
• The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.Krystal JH, D'Souza DC, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 2006, 10:235-52.
• Greater vulnerability to the amnestic effects of ketamine in males.Morgan CJ, Perry EB, Cho HS, Krystal JH, D'Souza DC. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology 2006, 187:405-14.
• Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D'Souza DC. Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2006, 31:1793-800.
• Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Srihari VH, Lee TS, Rohrbaugh RM, D'Souza DC. Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder. Schizophrenia Research 2006, 82:261-4.
• Psychiatric safety of ketamine in psychopharmacology research.Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O'Donnell E, Krystal JH, D'Souza DC. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192:253-60.
• Cannabinoids and psychosis.D'Souza DC. Cannabinoids and psychosis. International Review Of Neurobiology 2007, 78:289-326.
• Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2008, 33:2505-16.
• Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.Trevisan L, Petrakis IL, Pittman B, Gueorguieva R, D'Souza DC, Perry E, Limoncelli D, Krystal JH. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors. Alcoholism, Clinical And Experimental Research 2008, 32:36-42.
• Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.D'Souza DC, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 2009, 202:569-78.
• Cannabinoids and psychosis.Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. International Review Of Psychiatry (Abingdon, England) 2009, 21:152-62.
• Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia.Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14:690-7.
• Modelling psychosis.Curran HV, D'Souza DC, Robbins TW, Fletcher P. Modelling psychosis. Psychopharmacology 2009, 206:513-4.
• Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.Krystal JH, Mathew SJ, D'Souza DC, Garakani A, Gunduz-Bruce H, Charney DS. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010, 24:669-93.
• Capgras syndrome induced by ketamine in a healthy subject.Corlett PR, D'Souza DC, Krystal JH. Capgras syndrome induced by ketamine in a healthy subject. Biological Psychiatry 2010, 68:e1-2.
• [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista Brasileira De Psiquiatria (São Paulo, Brazil : 1999) 2010, 32 Suppl 1:S15-30.
• Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale.Sewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale. Schizophrenia Research 2010, 124:1-12.
• Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal Of Clinical Psychiatry 2010, 71:1475-81.
• Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence.Krystal JH, Petrakis IL, Limoncelli D, Nappi SK, Trevisan L, Pittman B, D'Souza DC, Suckow RF. Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2011, 36:701-10.
• Probing GABA receptor function in schizophrenia with iomazenil.Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC. Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2011, 36:677-83.
• Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2012, 37:1632-46.
• Cannabinoids, working memory, and schizophrenia.Skosnik PD, Ranganathan M, D'Souza DC. Cannabinoids, working memory, and schizophrenia. Biological Psychiatry 2012, 71:662-3.
• Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biological Psychiatry 2012, 72:785-94.
• Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, Haim AJ, Stroup TS. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal Of Clinical Psychiatry 2012, 73:1016-22.
• The effect of chronic cannabinoids on broadband EEG neural oscillations in humans.Skosnik PD, D'Souza DC, Steinmetz AB, Edwards CR, Vollmer JM, Hetrick WP, O'Donnell BF. The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2012, 37:2184-93.
• Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biological Psychiatry 2012, 72:871-9.
• Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia.D'Souza DC, Esterlis I, Carbuto M, Krasenics M, Seibyl J, Bois F, Pittman B, Ranganathan M, Cosgrove K, Staley J. Lower ß2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. The American Journal Of Psychiatry 2012, 169:326-34.
• The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D'Souza DC. The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2012, 219:885-96.
• Glutamatergic modulation of auditory information processing in the human brain.Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, Ford JM, Krystal JH, Mathalon DH. Glutamatergic modulation of auditory information processing in the human brain. Biological Psychiatry 2012, 71:969-77.
• Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.D'Souza DC, Singh N, Elander J, Carbuto M, Pittman B, Udo de Haes J, Sjogren M, Peeters P, Ranganathan M, Schipper J. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2012, 37:1036-46.
• Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study.Ralevski E, Perry EB, D'Souza DC, Bufis V, Elander J, Limoncelli D, Vendetti M, Dean E, Cooper TB, McKee S, Petrakis I. Preliminary findings on the interactive effects of IV ethanol and IV nicotine on human behavior and cognition: a laboratory study. Nicotine & Tobacco Research : Official Journal Of The Society For Research On Nicotine And Tobacco 2012, 14:596-606.
• Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal Of Neuropsychopharmacology / Official Scientific Journal Of The Collegium Internationale Neuropsychopharmacologicum (CINP) 2012, 15:1251-64.
• The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity.Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D'Souza DC, Gueorguieva R, He G, Leung HC, Ramani R, Anticevic A, Suckow RF, Morgan PT, Krystal JH. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2013, 38:2613-22.
• Spicing things up: synthetic cannabinoids.Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology 2013, 228:525-40.
• Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia.Boggs DL, Ranganathan M, Sewell RA, Madonick S, D'Souza DC. Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia. Schizophrenia Research 2013, 150:323-4.
• Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2013, 38:492-503.
• Glycine treatment of the risk syndrome for psychosis: report of two pilot studies.Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: report of two pilot studies. European Neuropsychopharmacology : The Journal Of The European College Of Neuropsychopharmacology 2013, 23:931-40.
• Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics.Boggs DL, Ranganathan M, Boggs AA, Bihday CM, Peluse BE, D'Souza DC. Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics. The Primary Care Companion For CNS Disorders 2013, 15.
• Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, Tyndale RF, Seibyl JP, Hatsukami DM, Cosgrove KP, O'Malley SS. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. The American Journal Of Psychiatry 2013, 170:399-407.
• Acute effects of THC on time perception in frequent and infrequent cannabis users.Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology 2013, 226:401-13.
• Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.Gunduz-Bruce H, Oliver S, Gueorguieva R, Forselius-Bielen K, D'Souza DC, Zimolo Z, Tek C, Kaliora S, Ray S, Petrides G. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia Research 2013, 143:344-7.
• Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans.Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry 2013, 18:1199-204.
• Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Current Pharmaceutical Design 2014, 20:5077-92.
• Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism.Ranganathan M, Sewell RA, Carbuto M, Elander J, Schnakenberg A, Radhakrishnan R, Pittman B, D'Souza DC. Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism. Psychopharmacology 2014, 231:2385-93.
• In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia.Esterlis I, Ranganathan M, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, Niciu MJ, Cosgrove KP, D'Souza DC. In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia. Biological Psychiatry 2014, 76:495-502.
• Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans.Mathalon DH, Ahn KH, Perry EB, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D'Souza DC. Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans. Frontiers In Psychiatry 2014, 5:3.
• Problems with the medicalization of marijuana.Wilkinson ST, D'Souza DC. Problems with the medicalization of marijuana. JAMA 2014, 311:2377-8.
• Gone to Pot - A Review of the Association between Cannabis and Psychosis.Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to Pot - A Review of the Association between Cannabis and Psychosis. Frontiers In Psychiatry 2014, 5:54.
• Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users.Skosnik PD, Krishnan GP, D'Souza DC, Hetrick WP, O'Donnell BF. Disrupted gamma-band neural oscillations during coherent motion perception in heavy cannabis users. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2014, 39:3087-99.
• Medicalization of marijuana--reply.Wilkinson ST, D'Souza DC. Medicalization of marijuana--reply. JAMA 2014, 312:1931-2.
• Impact of Cannabis Use on the Development of Psychotic Disorders.Wilkinson ST, Radhakrishnan R, D'Souza DC. Impact of Cannabis Use on the Development of Psychotic Disorders. Current Addiction Reports 2014, 1:115-128.
• GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC. GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2015, 40:2047-56.
• Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.Ahn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2015, 40:2822-31.
• Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015, 72:316-24.
• The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC. The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biological Psychiatry 2015, 78:805-13.
• Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Andrew Sewell R, Ranganathan M, Roach B, Ford J, D'Souza DC. Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans. Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology 2015, 40:2124-34.
• Medical Marijuana: Is the Cart Before the Horse?D'Souza DC, Ranganathan M. Medical Marijuana: Is the Cart Before the Horse? JAMA 2015, 313:2431-2.
• Testing differences in the activity of event-related potential sources: important implications for clinical researchers.Cortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D'Souza DC, Skosnik PD. Testing differences in the activity of event-related potential sources: important implications for clinical researchers. Clinical Neurophysiology : Official Journal Of The International Federation Of Clinical Neurophysiology 2015, 126:215-8.
• A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications.Wilkinson ST, Radhakrishnan R, D'Souza DC. A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications. The Journal Of Clinical Psychiatry 2016, 77:1050-64.
• Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials.DeWorsop D, Creatura G, Bluez G, Thurnauer H, Forselius-Bielen K, Ranganathan M, Deaso E, Bhat JA, D'Souza DC. Feasibility and success of cell-phone assisted remote observation of medication adherence (CAROMA) in clinical trials. Drug And Alcohol Dependence 2016, 163:24-30.
• Marijuana Legalization: Impact on Physicians and Public Health.Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana Legalization: Impact on Physicians and Public Health. Annual Review Of Medicine 2016, 67:453-66.
• Human Laboratory Studies on Cannabinoids and Psychosis.Sherif M, Radhakrishnan R, D'Souza DC, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry 2016, 79:526-38.
• Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.Ranganathan M, Cortes-Briones J, Radhakrishnan R, Thurnauer H, Planeta B, Skosnik P, Gao H, Labaree D, Neumeister A, Pittman B, Surti T, Huang Y, Carson RE, D'Souza DC. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia. Biological Psychiatry 2016, 79:997-1005.
• Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis.D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin MD, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry : Cognitive Neuroscience And Neuroimaging 2016, 1:60-67.
• Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology 2016, 233:3503-12.
• The early identification of psychosis: can lessons be learnt from cardiac stress testing?Gupta S, Ranganathan M, D'Souza DC. The early identification of psychosis: can lessons be learnt from cardiac stress testing? Psychopharmacology 2016, 233:19-37.
• Marijuana and Madness: Associations Between Cannabinoids and Psychosis.Ranganathan M, Skosnik PD, D'Souza DC. Marijuana and Madness: Associations Between Cannabinoids and Psychosis. Biological Psychiatry 2016, 79:511-3.
• The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients.Wilkinson ST, van Schalkwyk GI, Davidson L, D'Souza DC. The Formation of Marijuana Risk Perception in a Population of Substance Abusing Patients. The Psychiatric Quarterly 2016, 87:177-87.
• Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis.D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD. Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis. Biological Psychiatry : Cognitive Neuroscience And Neuroimaging 2016, 1:60-67.
• Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information.Ranganathan M, Radhakrishnan R, Addy PH, Schnakenberg-Martin AM, Williams AH, Carbuto M, Elander J, Pittman B, Andrew Sewell R, Skosnik PD, D'Souza DC. Tetrahydrocannabinol (THC) impairs encoding but not retrieval of verbal information. Progress In Neuro-psychopharmacology & Biological Psychiatry 2017, 79:176-183.
• Opposing Effects of Cannabis Use on Electroencephalographic Measures of Auditory Repetition Suppression in Schizophrenia and Healthy Controls.Skosnik PD, D'Souza DC. Opposing Effects of Cannabis Use on Electroencephalographic Measures of Auditory Repetition Suppression in Schizophrenia and Healthy Controls. Biological Psychiatry : Cognitive Neuroscience And Neuroimaging 2017, 2:209-211.
• Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318:132-145.
• Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242.Ranganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, Gupta S, Cahill J, Sherif MA, Mancuso J, Zumpano L, D'Souza DC. Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242. Molecular Psychiatry 2017, 22:1633-1640.
• Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.Boggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, Sewell RA, Ranganathan M, D'Souza DC. Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia. Schizophrenia Research 2018, 194:62-69.
• Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.Hamilton HK, D'Souza DC, Ford JM, Roach BJ, Kort NS, Ahn KH, Bhakta S, Ranganathan M, Mathalon DH. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia. Schizophrenia Research 2018, 191:87-94.
• Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.Schindler EAD, Wallace RM, Sloshower JA, D'Souza DC. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9:177.
• Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects.D'Souza DC, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry 2018, 84:413-421.
• Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?Taylor JJ, Krystal JH, D'Souza DC, Gerrard JL, Corlett PR. Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS? Schizophrenia Research 2018, 195:455-462.
• The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 2018, 235:1923-1932.
• Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET.Radhakrishnan R, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Williams W, Morris E, D'Souza DC, Huang Y, Carson RE, Matuskey D. Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2018, 59:1445-1450.
• The Psychiatric Consequences of Cannabinoids.De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza DC. The Psychiatric Consequences of Cannabinoids. Clinical Therapeutics 2018, 40:1448-1456.
• Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans.Skosnik PD, Hajós M, Cortes-Briones JA, Edwards CR, Pittman BP, Hoffmann WE, Sewell AR, D'Souza DC, Ranganathan M. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Neuropharmacology 2018, 135:412-423.
• The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans.Boggs DL, Cortes-Briones JA, Surti T, Luddy C, Ranganathan M, Cahill JD, Sewell AR, D'Souza DC, Skosnik PD. The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans. Journal Of Psychopharmacology (Oxford, England) 2018, 32:1308-1318.
• Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, Skosnik PD. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet. Psychiatry 2019, 6:35-45.
• Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence.Orr C, Spechler P, Cao Z, Albaugh M, Chaarani B, Mackey S, D'Souza D, Allgaier N, Banaschewski T, Bokde ALW, Bromberg U, Büchel C, Burke Quinlan E, Conrod P, Desrivières S, Flor H, Frouin V, Gowland P, Heinz A, Ittermann B, Martinot JL, Paillère Martinot ML, Nees F, Papadopoulos Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Radhakrishnan R, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H. Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence. The Journal Of Neuroscience : The Official Journal Of The Society For Neuroscience 2019, 39:1817-1827.
• Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study.Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophrenia Research 2019, 206:291-299.
• Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.Gupta S, De Aquino JP, D'Souza DC, Ranganathan M. Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis. Psychopharmacology 2019, 236:2635-2640.
• Medical Marijuana: What Physicians Need to Know.Radhakrishnan R, Ranganathan M, D'Souza DC. Medical Marijuana: What Physicians Need to Know. The Journal Of Clinical Psychiatry 2019, 80.
• Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans.Ranganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D'Souza DC. Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2019, 236:3209-3219.
• Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls.Roach BJ, D'Souza DC, Ford JM, Mathalon DH. Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls. NeuroImage. Clinical 2019, 23:101878.
• Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure.D'Souza DC, Ganesh S, Cortes-Briones J, Campbell MH, Emmanuel MK. Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. Psychological Medicine 2020, 50:2452-2459.
• In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET.Radhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research. Neuroimaging 2020, 295:111007.